Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 5.52B +70.0% |
| Revenue (ttm) | 290.54M +54.9% |
| Net Income | 197.22M |
| EPS | 9.19 |
| Shares Out | 19.94M |
| PE Ratio | 30.13 |
| Forward PE | 40.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 180,222 |
| Open | 280.53 |
| Previous Close | 280.65 |
| Day's Range | 270.77 - 280.53 |
| 52-Week Range | 161.82 - 326.63 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 342.82 (+23.77%) |
| Earnings Date | Aug 6, 2026 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $342.82, which is an increase of 23.77% from the latest price.
News
Ligand Pharmaceuticals Transcript: 17th Annual Midwest IDEAS Conference
The company has rapidly scaled its royalty aggregation strategy, highlighted by the XOMA acquisition, which doubled its portfolio and is immediately accretive. Strong financials, a robust pipeline, and disciplined investment processes position it for significant near- and long-term growth.
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor confe...
Ligand Pharmaceuticals Slides: Corporate presentation
Ligand Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Ligand price target raised to $390 from $387 at Citi
Citi raised the firm’s price target on Ligand (LGND) to $390 from $387 and keeps a Buy rating on the shares.
Ligand initiated with an Outperform at Leerink
Leerink initiated coverage of Ligand (LGND) with an Outperform rating and $330 price target
Ligand price target raised to $345 from $340 at RBC Capital
RBC Capital analyst Douglas Miehm raised the firm’s price target on Ligand (LGND) to $345 from $340 and keeps an Outperform rating on the shares.
Ligand price target raised to $358 from $289 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Ligand (LGND) to $358 from $289 and keeps a Buy rating on the shares following the Q2 report. Ligand’s…
Ligand Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw revenue and EPS surge, driven by strong royalty growth and the transformative XOMA acquisition, which doubled the late-stage pipeline and added over 120 assets. The company raised $700 million in zero coupon convertible notes, reaffirmed robust guidance, and expects significant near-term catalysts across a diversified portfolio.
Ligand Pharmaceuticals Earnings release: Q2 2026
Ligand Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q2 2026
Ligand Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Ligand Pharmaceuticals Quarterly report: Q2 2026
Ligand Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ligand reports Q2 adjusted EPS $2.37, consensus $1.97
Reports Q2 revenue $63.69M, consensus $61.26M. “Ligand (LGND) delivered another strong quarter, with royalty revenue growing 32% year-over-year and continued momentum from Filspari following its FSGS ...
Ligand narrows FY26 adjusted EPS view to $9.00-$9.50 from $8.50-$9.50
Consensus $9.20. Backs FY26 revenue view $270M-$310M, consensus $287.44M. The company said, “Ligand (LGND) is reaffirming its 2026 full-year revenue guidance and is raising the low end of its adjusted...
Ligand price target raised to $326 from $285 at Oppenheimer
Oppenheimer raised the firm’s price target on Ligand (LGND) to $326 from $285 and keeps an Outperform rating on the shares. The firm says its new model reflects the Xoma…
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 202...
Ligand resumed with a Buy at Citi
Citi resumed coverage of Ligand (LGND) with a Buy rating and $387 price target following the close of the Xoma acquisition. The firm views the deal as “highly compelling” and…
Ligand price target raised to $345 from $330 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt raised the firm’s price target on Ligand (LGND) to $345 from $330 and keeps a Buy rating on the shares. Following investor meetings, the firm notes…
Ligand price target raised to $335 from $275 at Benchmark
Benchmark analyst Robert Wasserman raised the firm’s price target on Ligand (LGND) to $335 from $275 and keeps a Buy rating on the shares after the company announced the completion…
Ligand price target raised to $340 from $262 at RBC Capital
RBC Capital raised the firm’s price target on Ligand (LGND) to $340 from $262 and keeps an Outperform rating on the shares. The firm is updating its model and price…
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating...
XOMA Royalty Announces Closing of Its Acquisition by Ligand
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisitio...
Ligand price target raised to $388 from $266 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $388 from $266 and keeps a Buy rating on the shares. Despite strong share performance, Ligand’s growth…
Ligand price target raised to $332 from $255 at Stifel
Stifel analyst Annabel Samimy raised the firm’s price target on Ligand (LGND) to $332 from $255 and keeps a Buy rating on the shares. The firm’s estimates now incorporate expanded…
Ligand Announces Closing of Convertible Senior Notes Offering
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset...
Ligand prices upsized $625M convertible senior note offering
Ligand (LGND) Pharmaceuticals announced the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 in a private placement to persons reasonably believed to be q...